Literature DB >> 19054690

Successful treatment of mitomycin-induced thrombotic thrombocytopenic purpura with rituximab.

Adedayo A Onitilo, Jessica M Engel, Lawrence H Clouse, Kristin M Gerndt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19054690     DOI: 10.1016/j.jvir.2008.10.025

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


× No keyword cloud information.
  6 in total

Review 1.  Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis.

Authors:  Nay M Tun; Gina M Villani
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

2.  Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: a case report.

Authors:  Keith Siau; Mohini Varughese
Journal:  Med Oncol       Date:  2009-10-22       Impact factor: 3.064

3.  Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report.

Authors:  Wade Iams; Kathyrn Eby Beckermann; Anne T Neff; Ingrid A Mayer; Vandana Gupta Abramson
Journal:  Med Oncol       Date:  2013-04-07       Impact factor: 3.064

4.  Slow, but complete, resolution of mitomycin-induced refractory thrombotic thrombocytopenic purpura after rituximab treatment.

Authors:  Mi Jin Hong; Hong Ghi Lee; Mina Hur; Sung Yong Kim; Yo Han Cho; So Young Yoon
Journal:  Korean J Hematol       Date:  2011-03-15

5.  Pediatric onco-nephrology: time to spread the word : Part I: early kidney involvement in children with malignancy.

Authors:  Arwa Nada; Jennifer G Jetton
Journal:  Pediatr Nephrol       Date:  2020-11-27       Impact factor: 3.714

6.  Mitomycin-C-Induced TTP/HUS Treated Successfully with Rituximab: Case Report and Review of the Literature.

Authors:  Gunjan Shah; Hanah Yamin; Hedy Smith
Journal:  Case Rep Hematol       Date:  2013-05-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.